Spectral AI Croissance future
Future contrôle des critères 0/6
Les bénéfices de Spectral AI devraient diminuer de 13.2% par an tandis que son chiffre d'affaires annuel devrait croître de 2.1% par an. Le BPA devrait croître de en baisse de 6.3% par an.
Informations clés
-13.2%
Taux de croissance des bénéfices
-6.31%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 16.4% |
| Taux de croissance des recettes | 2.1% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 01 Jun 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • Jun 17
MDAI: FDA Burn Care Clearance Will Drive Future Commercialization Potential
Spectral AI's analyst price target has moved from $3 to $4, with analysts highlighting the recent FDA clearance of the DeepView System for Burn Centers, Trauma Centers, and Emergency Departments as a key factor in their updated view. What’s in the News for Spectral AI The U.S. FDA has granted De Novo Classification for Spectral AI’s DeepView System, authorizing commercial distribution for burn care use in burn centers, trauma centers, and emergency departments.
Mise à jour du récit • Jun 03
MDAI: FDA Clearance And BARDA Funding Will Support Future Burn Preparedness
Spectral AI's analyst price target has increased by $1 to $4, with analysts citing the recent FDA clearance of its DeepView System for Burn Centers, Trauma Centers, and Emergency Departments as a key driver of the reassessment. What's in the News U.S. FDA granted De Novo Classification for Spectral AI's DeepView System, authorizing commercial distribution for burn care in burn centers, trauma centers, and emergency departments.
Mise à jour du récit • May 24
Spectral AI (MDAI): DeepView AI Automated Wound Imaging System Granted FDA Approval!!!
Well this is the news I and many others have been waiting ten months for, and certainly in my case expecting given the information in the public domain… the first of its kind automated wound imaging and assessment device has been granted US FDA approval!!! Years of work by the dedicated team at Spectral AI and partners such as the US Government’s BARDA have put this relatively small company on the map, with a device that offers burn specialists and clinicians the opportunity to potentially improve patient outcomes and hopefully save time and money for all concerned.Article d’analyse • May 15
Analyst Estimates: Here's What Brokers Think Of Spectral AI, Inc. (NASDAQ:MDAI) After Its First-Quarter Report
The analysts might have been a bit too bullish on Spectral AI, Inc. ( NASDAQ:MDAI ), given that the company fell short...Mise à jour du récit • May 08
MDAI: BARDA Funding And New Leadership Will Support Future Burn Preparedness
Analysts have trimmed their price target on Spectral AI to $6.00, reflecting slightly lower profit margin assumptions and a higher forward P/E multiple, even though their fair value estimate remains at $6.00 and discount rate expectations have eased. What's in the News Spectral AI received $31.7 million in immediate, non dilutive funding from the Biomedical Advanced Research and Development Authority to support additional feature development for its DeepView System, alongside a commitment from the company to contribute $9.7 million to total development costs (BARDA contract 75A50123C00049).Mise à jour du récit • Apr 21
MDAI: BARDA Funding And New Leadership Will Support Future Commercialization Potential
Analysts have updated their price targets on Spectral AI to reflect revised assumptions for discount rates, revenue growth, profit margins, and a higher forward P/E. These changes have resulted in a revised assessment of the potential upside in the shares.Mise à jour du récit • Apr 06
MDAI: BARDA Funding And Leadership Transition Will Support Future Burn Preparedness
Analysts have nudged their Spectral AI price target to $6.00, citing small adjustments to assumptions on discount rate, revenue trends, profit margins, and a very high future P/E multiple as key drivers of the updated view. What's in the News Spectral AI received $31.7 million in immediate, non dilutive funding from the Biomedical Advanced Research and Development Authority to support additional feature development for its DeepView System, an AI driven burn wound imaging technology, alongside a company commitment of $9.7 million to total development costs (BARDA contract 75A50123C00049).Article d’analyse • Mar 27
News Flash: Analysts Just Made A Stunning Upgrade To Their Spectral AI, Inc. (NASDAQ:MDAI) Forecasts
Shareholders in Spectral AI, Inc. ( NASDAQ:MDAI ) may be thrilled to learn that the analysts have just delivered a...Mise à jour du récit • Mar 23
MDAI: BARDA Funding Will Support Future Burn Preparedness Commercialization Potential
Analysts have trimmed their price target on Spectral AI from $7.45 to $6.00 as they now apply a higher discount rate, expect a 28.16% decline in revenue growth, see profit margins at 12.86%, and use a much higher forward P/E multiple of 254.14x in their models. What's in the News Spectral AI received $31.7 million in immediate, non-dilutive funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to accelerate additional features for its DeepView System, with the company committing a further $9.7 million of its own capital to the project (Key Developments).Mise à jour du récit • Mar 09
MDAI: New CEO Appointment Will Support Future Margin Recovery Potential
Analysts have trimmed their Spectral AI price target to $3.00, citing slightly higher discount rates, softer revenue growth expectations, a lower projected profit margin, and a higher assumed future P/E multiple in their updated model. What's in the News Spectral AI appointed Vincent S.Mise à jour du récit • Feb 23
MDAI: Leadership Transition And Commercialization Progress Will Support Future Margin Recovery
Narrative Update on Spectral AI Analysts have kept their Spectral AI price target steady at $3.00, with unchanged fair value assumptions and only small tweaks to the discount rate, revenue growth, profit margin, and future P/E inputs. These adjustments support a largely unchanged outlook.Nouveau récit • Feb 14
Spectral AI: First of Its Kind Automated Wound Healing Prediction
Overview Spectral AI is an artificial intelligence business offering predictive wound diagnostics designed to facilitate faster and more accurate treatment decisions in wound care. Spectral’s shares are traded as NASDAQ: MDAI.Mise à jour du récit • Feb 07
MDAI: Contract Timing Shift Will Support Future Margin Recovery And Revenue Upside
Analysts have adjusted their price target on Spectral AI to reflect a slightly lower discount rate, a small change in expected revenue contraction, and an updated future P/E of about 86x, while keeping fair value steady at US$3.00. What's in the News Spectral AI revised its earnings guidance for fiscal year 2025, reducing expected revenue guidance from US$21.5 million to US$18.5 million.Article d’analyse • Jan 27
Spectral AI, Inc. (NASDAQ:MDAI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Spectral AI, Inc. ( NASDAQ:MDAI ) shareholders are no doubt pleased to see that the share price has bounced 29% in the...Mise à jour du récit • Jan 23
MDAI: Contract Timing Shift Will Support Future Margin And Revenue Upside
Analysts now estimate Spectral AI's fair value at US$3.00 per share, unchanged from the prior US$3.00 view, as minor adjustments to the discount rate, revenue outlook, profit margin and future P/E assumptions leave their overall price target the same. What's in the News Spectral AI revised its revenue guidance for fiscal 2025 to US$18.5 million from US$21.5 million, reflecting updated expectations for the year (company guidance).Mise à jour du récit • Jan 08
MDAI: Future Contract Timing Shift Will Support Stronger Profit Margins
Analysts have trimmed their price targets on Spectral AI to US$3.00, pointing to updated assumptions that include a slightly higher discount rate, a smaller revenue decline, a higher profit margin outlook, and a lower future P/E multiple of about 88x. What's in the News Spectral AI reduced its revenue guidance for fiscal 2025 from US$21.5 million to US$18.5 million, citing timing of work on its BARDA contract and effects from the current US government shutdown (Key Developments).Mise à jour du récit • Dec 14
MDAI Future Revenue Shift From Contracts Will Support Stronger Profit Margins
Analysts have trimmed their price target on Spectral AI to reflect a modestly lower fair value estimate of 3.0 dollars from 3.5 dollars. They cited slightly higher perceived risk, even as outlooks improve for revenue contraction and profit margins, along with a marginally more attractive future earnings multiple.Article d’analyse • Nov 28
Spectral AI, Inc. (NASDAQ:MDAI) Shares Could Be 26% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Spectral AI fair value estimate is US$2.14 Current share price...Article d’analyse • Nov 28
The Market Doesn't Like What It Sees From Spectral AI, Inc.'s (NASDAQ:MDAI) Revenues Yet As Shares Tumble 27%
Spectral AI, Inc. ( NASDAQ:MDAI ) shareholders won't be pleased to see that the share price has had a very rough month...Article d’analyse • Oct 23
At US$2.24, Is Spectral AI, Inc. (NASDAQ:MDAI) Worth Looking At Closely?
Spectral AI, Inc. ( NASDAQ:MDAI ), might not be a large cap stock, but it led the NASDAQCM gainers with a relatively...Article d’analyse • Sep 06
Market Cool On Spectral AI, Inc.'s (NASDAQ:MDAI) Revenues Pushing Shares 25% Lower
Spectral AI, Inc. ( NASDAQ:MDAI ) shareholders won't be pleased to see that the share price has had a very rough month...Article d’analyse • Aug 16
Spectral AI, Inc. (NASDAQ:MDAI) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.09
NasdaqCM:MDAI 1 Year Share Price vs Fair Value Explore Spectral AI's Fair Values from the Community and select yours...Article d’analyse • Jul 29
Estimating The Intrinsic Value Of Spectral AI, Inc. (NASDAQ:MDAI)
Key Insights The projected fair value for Spectral AI is US$2.91 based on 2 Stage Free Cash Flow to Equity Spectral...Article d’analyse • Jun 22
The Market Lifts Spectral AI, Inc. (NASDAQ:MDAI) Shares 50% But It Can Do More
Spectral AI, Inc. ( NASDAQ:MDAI ) shareholders have had their patience rewarded with a 50% share price jump in the last...Article d’analyse • Jun 22
The Market Lifts Spectral AI, Inc. (NASDAQ:MDAI) Shares 50% But It Can Do More
The Spectral AI, Inc. ( NASDAQ:MDAI ) share price has done very well over the last month, posting an excellent gain of...
Nouveau récit • May 06
FDA Submission Success Will Advance DeepView Global Opportunities
Successful burn validation study and international expansion strengthen FDA submission, potentially accelerating approval and driving future revenue growth.Article d’analyse • Mar 08
Take Care Before Jumping Onto Spectral AI, Inc. (NASDAQ:MDAI) Even Though It's 28% Cheaper
Spectral AI, Inc. ( NASDAQ:MDAI ) shareholders that were waiting for something to happen have been dealt a blow with a...Article d’analyse • Feb 10
Estimating The Intrinsic Value Of Spectral AI, Inc. (NASDAQ:MDAI)
Key Insights Spectral AI's estimated fair value is US$2.15 based on 2 Stage Free Cash Flow to Equity With US$2.06 share...Article d’analyse • Dec 18
Investors Still Aren't Entirely Convinced By Spectral AI, Inc.'s (NASDAQ:MDAI) Revenues Despite 39% Price Jump
Despite an already strong run, Spectral AI, Inc. ( NASDAQ:MDAI ) shares have been powering on, with a gain of 39% in...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 25 | -21 | N/A | N/A | 2 |
| 12/31/2027 | 23 | -19 | N/A | N/A | 3 |
| 12/31/2026 | 19 | -18 | N/A | N/A | 3 |
| 3/31/2026 | 17 | -14 | -12 | -12 | N/A |
| 12/31/2025 | 20 | -8 | -10 | -10 | N/A |
| 9/30/2025 | 23 | -16 | -7 | -7 | N/A |
| 6/30/2025 | 28 | -14 | -6 | -6 | N/A |
| 3/31/2025 | 30 | -9 | -8 | -8 | N/A |
| 12/31/2024 | 30 | -15 | -9 | -9 | N/A |
| 9/30/2024 | 27 | -11 | -12 | -12 | N/A |
| 6/30/2024 | 23 | -20 | -16 | -16 | N/A |
| 3/31/2024 | 19 | -20 | -12 | -12 | N/A |
| 12/31/2023 | 18 | -21 | -13 | -13 | N/A |
| 9/30/2023 | 19 | -19 | -11 | -11 | N/A |
| 6/30/2023 | 22 | -9 | -7 | -7 | N/A |
| 3/31/2023 | 25 | -6 | -4 | -4 | N/A |
| 12/31/2022 | 25 | -3 | -1 | -1 | N/A |
| 9/30/2022 | 23 | -3 | -2 | -2 | N/A |
| 6/30/2022 | 20 | -4 | -2 | -2 | N/A |
| 3/31/2022 | 18 | -5 | -3 | -3 | N/A |
| 12/31/2021 | 15 | -5 | -3 | -3 | N/A |
| 9/30/2021 | 16 | -4 | 0 | 0 | N/A |
| 6/30/2021 | 17 | -3 | 2 | 2 | N/A |
| 3/31/2021 | 17 | -1 | 3 | 3 | N/A |
| 12/31/2020 | 17 | 1 | 4 | 4 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: MDAI devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: MDAI devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: MDAI devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de MDAI ( 2.1% par an) devrait croître plus lentement que le marché de US ( 12.7% par an).
Croissance élevée des revenus: Le chiffre d'affaires de MDAI ( 2.1% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de MDAI devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/30 23:30 |
| Cours de l'action en fin de journée | 2026/06/30 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Spectral AI, Inc. est couverte par 5 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Michael Gorman | BTIG |
| Carl Byrnes | Northland Capital Markets |
| Vadim Alexandre Khalil | SP Angel Corporate Finance LLP |